Dermatitis: Clinical Trials

217 trials for Dermatitis, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

217 completed. 217 Phase 3, 10 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 3217Completed 217
Phase 210Completed 10

Follow Dermatitis: new trials by email Literature Review of Dermatitis trials Research Report on Dermatitis

Trials (filtered) newest first · largest first

All 217 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study to Investigate Improvement in Pruritus of Lichen Simplex Chronicus With Dupilumab Injections Compared With Placebo in Male and Female Participants Aged at Least 18 Years (STYLE 1)
Dupilumab, Placebo - Lichen Simplex Chronicus
Phase 3CompletedSanofi1422024-11-282026-09-11
A Study to Investigate Improvement in Pruritus of Lichen Simplex Chronicus With Dupilumab Injections Compared With Placebo in Male and Female Participants Aged at Least 18 Years (STYLE 2)
Dupilumab, Placebo - Lichen Simplex Chronicus
Phase 3CompletedSanofi1382024-11-252026-09-11
Efficacy and Safety of Roflumilast Cream in Subjects With Atopic Dermatitis
Roflumilast Cream 0.15%, Vehicle cream - Atopic Dermatitis (AD)
Phase 3CompletedHangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.3542024-11-212025-09-02
To Evaluate the Phase III Clinical Trial of TQH2722 Injection in the Treatment of Moderate to Severe Atopic Dermatitis
TQH2722 injection, Placebo of TQH2722 injection - Atopic Dermatitis
Phase 3CompletedShanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.5002024-10-082026-11-09
Evaluation of 611 in Combination With Topical Corticosteroid in Participants With Moderate to Severe Atopic Dermatitis
611, Placebo, Topical corticosteroid - Dermatitis, Atopic, Eczema, Atopic
Phase 3CompletedSunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.4172024-09-232026-09-17
A Study to Evaluate the Efficacy and Safety of SIM0718 in Adult and Adolescent Patients With Moderate to Severe Atopic Dermatitis
SIM0718 Injection - Atopic Dermatitis
Phase 3CompletedSimcere Pharmaceutical Co., Ltd2592024-07-042026-03-31
Lebrikizumab Pen Ease of Use in Participants With Atopic Dermatitis
Lebrikizumab Pen - Atopic Dermatitis
Phase 3CompletedEli Lilly and Company552024-06-042025-07-29
A Study to Evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis
Ruxolitinib Cream, Vehicle Cream - Atopic Dermatitis
Phase 3CompletedIncyte Corporation2412024-04-262026-10-15
A Study of Lebrikizumab (LY3650150) With/Without Topical Corticosteroid Treatment in Participants With Moderate-to-Severe Atopic Dermatitis
Placebo, Lebrikizumab, Topical Corticosteroid - Atopic Dermatitis
Phase 3CompletedEli Lilly and Company3012024-04-242026-10-16
Efficacy and Safety of Polisorb® MP in the Complex Therapy of Patients With Atopic Dermatitis
Colloidal Silicon Dioxide, Basic Therapy for Atopic Dermatitis - Atopic Dermatitis
Phase 3CompletedPolisorb Joint Stock Company1612024-04-102026-11-10
A Study With Self-administered Rocatinlimab in Adolescent and Adult Participants With Moderate-to-severe Atopic Dermatitis
Rocatinlimab Prefilled Syringe, Rocatinlimab AI - Atopic Dermatitis
Phase 3CompletedAmgen1512024-04-022026-03-25
Study of CM310 Injection in Adolescent Subjects With Atopic Dermatis
CM310, placebo - Atopic Dermatitis
Phase 3CompletedKeymed Biosciences Co.Ltd1802024-03-212025-10-02
A Phase 3 Study of LNK01001 Capsule in Subjects With Moderate to Severe Atopic Dermatitis.
LNK01001, Placebo - Atopic Dermatitis
Phase 3CompletedLynk Pharmaceuticals Co., Ltd3562024-02-062026-04-13
Evaluation of 611(Recombinant Humanized Anti-interleukin-4 Receptor Alpha IgG4 Monoclonal Antibody) in Chinese Adults With Moderate to Severe Atopic Dermatitis
611, Matching placebo - Dermatitis, Atopic
Phase 3CompletedSunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.5192024-01-222026-01-15
A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis on Background Topical Corticosteroids
Amlitelimab, Placebo, Topical corticosteroids - Dermatitis Atopic
Phase 3CompletedSanofi6432024-01-182026-08-13
A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis (COAST 2)
Amlitelimab, Placebo - Dermatitis Atopic
Phase 3CompletedSanofi5892023-12-212026-08-13
Effectiveness and Safety of Lebrikizumab Treatment in Adults and Adolescents With Moderate-to-Severe Atopic Dermatitis
Lebrikizumab - Atopic Dermatitis, Eczema
Phase 3CompletedAlmirall, S.A.2602023-11-202026-07-17
A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis
Amlitelimab, Placebo - Dermatitis Atopic
Phase 3CompletedSanofi6012023-11-082026-07-22
A Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Delgocitinib Cream in Chinese Adults and Adolescents With Moderate to Severe Chronic Hand Eczema
Delgocitinib, Vehicle cream - Chronic Hand Eczema
Phase 3CompletedLEO Pharma3622023-09-052025-09-25
A 32-week Trial to Evaluate the Efficacy and Safety of Tralokinumab in Subjects With Moderate-to-severe Atopic Hand Eczema Who Are Candidates for Systemic Therapy
Tralokinumab, Placebo - Atopic Dermatitis, Atopic Hand Eczema
Phase 3CompletedLEO Pharma2352023-08-282026-10-22

Showing 20 of 217. Sign in to see all of them.

Narrower conditions

Dermatitis, Atopic (157)  ·  Eczema (56)  ·  Skin Diseases (18)  ·  Radiodermatitis (12)  ·  Breast Neoplasms (9)  ·  Pruritus (9)  ·  Neurodermatitis (8)  ·  Dermatitis, Seborrheic (5)  ·  Hand-Foot Syndrome (5)  ·  Hypersensitivity (5)  ·  Psoriasis (5)  ·  Genetic Diseases, Inborn (4)  ·  Hypersensitivity, Immediate (4)  ·  Immune System Diseases (4)

Broader conditions

Skin and Connective Tissue Diseases (217)  ·  Skin Diseases (199)  ·  Skin Diseases, Eczematous (181)  ·  Immune System Diseases (159)  ·  Hypersensitivity (158)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (157)  ·  Genetic Diseases, Inborn (153)  ·  Hypersensitivity, Immediate (153)  ·  Skin Diseases, Genetic (153)  ·  Pathological Conditions, Signs and Symptoms (15)  ·  Wounds and Injuries (12)  ·  Neoplasms (11)  ·  Neoplasms by Site (11)  ·  Radiation Injuries (11)

Interventions

dupilumab (20)  ·  Adrenal Cortex Hormones (13)  ·  lebrikizumab (13)  ·  pimecrolimus (10)  ·  tralokinumab (9)  ·  abrocitinib (8)  ·  Tacrolimus (7)  ·  baricitinib (7)  ·  difamilast (7)  ·  secukinumab (6)  ·  upadacitinib (6)  ·  nemolizumab (4)  ·  Calcineurin Inhibitors (3)  ·  Cyclosporine (3)  ·  Alitretinoin (2)

Sponsors

Eli Lilly and Company (18)  ·  Pfizer (12)  ·  LEO Pharma (10)  ·  Regeneron Pharmaceuticals (10)  ·  Sanofi (10)  ·  Novartis Pharmaceuticals (8)  ·  Amgen (7)  ·  Incyte Corporation (7)  ·  AbbVie (6)  ·  Astellas Pharma Inc (6)  ·  Novartis (5)  ·  Organon and Co (5)  ·  Galderma R&D (4)  ·  Otsuka Pharmaceutical Co., Ltd. (4)  ·  Almirall, S.A. (3)

Countries

United States (103)  ·  Germany (67)  ·  Canada (65)  ·  Poland (57)  ·  France (49)  ·  Spain (47)  ·  Japan (45)  ·  Italy (44)  ·  United Kingdom (44)  ·  South Korea (38)  ·  China (36)  ·  Australia (35)  ·  Hungary (32)  ·  Czechia (30)  ·  Belgium (27)

Top investigators

Diana Villalobos (3)  ·  Osamu Sato (3)

Results publications

PMID 39588375, PMID 42162528, PMID 33826132, PMID 40993471, PMID 34406619, PMID 36255569, PMID 36723913, PMID 38896380, PMID 40028832, PMID 31066001, PMID 33165005, PMID 33453450, PMID 34142350, PMID 35636689, PMID 36808602, PMID 39104653, PMID 40555305, PMID 41118053, PMID 31407311, PMID 31424712, PMID 34037993, PMID 34275122, PMID 34688290, PMID 34726270, PMID 34743361, PMID 34897582, PMID 35305260, PMID 35342978, PMID 36152216, PMID 36749121, PMID 38777187, PMID 39110139, PMID 40085349, PMID 40383273, PMID 40457140, PMID 40600584, PMID 41206702, PMID 42365219, PMID 27417017, PMID 27690741, PMID 28503712, PMID 30345457, PMID 30791102, PMID 30972746, PMID 32318744, PMID 32574023, PMID 33000465, PMID 33222559, PMID 33481203, PMID 33658996

NIH funding

2018 (11), 2019 (11), 2017 (8), 2023 (5), 2016 (4), 2015 (2), 2008 (1), 2014 (1), U10CA037420 (1)